相关临床试验
1552
157 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1885
终止
32
2.1%
招募中
203
13.1%
暂停
1
0.1%
撤回
30
1.9%
进行中（未招募）
39
2.5%
Unknown
303
19.5%
已完成
826
53.2%
Enrolling By Invitation
6
0.4%
尚未招募
112
7.2%
暂无批准数据
- Korean researchers used an oxygen-to-nitrogen atom swap to convert the furan group in natural products into pyrroles, dramatically altering biological activity. - The 15N-labeled limonin analog 15N-LIMO bound metabolic and mitochondrial proteins such as NNT instead of the kinases targeted by parent limonin. - Both limonin and 15N-LIMO showed antifibrotic activity through different mechanisms, with 15N-LIMO acting on mitochondrial redox systems and proving less cytotoxic. - A separate Ritsumeikan team reported a chlorine-guided, room-temperature method that deletes a carbonyl group from hydroxycoumarins to form coumaranones in over 99% yield.
- The Korea National Institute of Health will add normal organ tissues from deceased donors, such as hearts, to its Innovative Biobank Consortium Support Project to strengthen precision medicine research. - Normal tissues will serve as control data for comparison with diseased tissues, helping elucidate disease causes and progression tailored to individual genetic characteristics. - The project has secured 3,648 high-quality biospecimens and produced 46 SCI papers, 10 patents, 3 technology transfers, and 1 commercialization, with research productivity 3.1 times the national R&D average. - The new "Cadaveric Normal Tissue Consortium," led by Professor Oh Ji-won of Yonsei University, aims to link living and post-mortem human resources into a national research foundation.
- A KAIST-Yonsei University team has identified the molecular mechanism by which amino acid signals trigger mTORC1-dependent cell growth via phosphorylation and release of LARS1 from the multi-tRNA synthetase complex. - Cryo-EM structural analysis revealed that nutrient-induced phosphorylation of LARS1 weakens its binding to IARS1, allowing LARS1 to dissociate from the MSC and activate mTORC1. - The findings suggest a more selective anticancer strategy that targets upstream growth signaling rather than directly inhibiting mTORC1, potentially sparing normal cells. - The study was published in Nature Communications on June 11 and was supported by the National Research Foundation of Korea.
- Cheon Jin-woo, a Yonsei University professor and founding director of the IBS Center for Nanomedicine, has received the 2026 Top Scientist and Technologist Award of Korea, the nation's highest scientific honor. - He was recognized for pioneering nanomedicine by integrating nanochemistry with biotechnology to advance disease diagnosis, cell therapy, and neural circuit modulation. - Cheon's magnetogenetics technologies enable wireless, remote control of neuronal activity in living animals using magnetic fields, published in Nature Materials (2021) and Nature Nanotechnology (2024). - The award includes a presidential citation and a 300 million won ($196,000) cash prize, to be presented at the 2026 World Congress of Korean Scientists and Engineers.
